{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Anderson RA"],"funding":["Medical Research Foundation","Cancer Research UK","Medical Research Council","MRF_"],"pagination":["1328-1337"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6167406"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["19(10)"],"pubmed_abstract":["<h4>Background</h4>Adverse effects on reproductive function are a key concern in young women treated with chemotherapy for advanced Hodgkin's lymphoma. We aimed to identify risk factors for the extent of ovarian damage in women with Hodgkin's lymphoma treated with different chemotherapy regimens to inform accurate advice on options for fertility preservation.<h4>Methods</h4>We recruited female participants from the randomised phase 3 RATHL trial, aged 18-45 years, based on availability of participants at recruiting sites in the UK. The RATHL trial key inclusion criteria were histologically confirmed classic Hodgkin's lymphoma, stage IIB-IV or IIA with adverse features (bulky disease or more than two sites of involvement), no previous treatments, and a performance status of 0-3. As part of "],"journal":["The Lancet. Oncology"],"pubmed_title":["Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial."],"pmcid":["PMC6167406"],"funding_grant_id":["C0311","G1100357","MR/N022556/1","CRUK/07/033","9619"],"pubmed_authors":["Clifton-Hadley L","Roberts T","Hatton C","McKay P","Scott FM","Anderson RA","Rowntree C","Stevens L","Kirkwood AA","Kalakonda N","Milligan DW","Patrick P","Johnson PWM","Remedios R"],"additional_accession":[]},"is_claimable":false,"name":"Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial.","description":"<h4>Background</h4>Adverse effects on reproductive function are a key concern in young women treated with chemotherapy for advanced Hodgkin's lymphoma. We aimed to identify risk factors for the extent of ovarian damage in women with Hodgkin's lymphoma treated with different chemotherapy regimens to inform accurate advice on options for fertility preservation.<h4>Methods</h4>We recruited female participants from the randomised phase 3 RATHL trial, aged 18-45 years, based on availability of participants at recruiting sites in the UK. The RATHL trial key inclusion criteria were histologically confirmed classic Hodgkin's lymphoma, stage IIB-IV or IIA with adverse features (bulky disease or more than two sites of involvement), no previous treatments, and a performance status of 0-3. As part of ","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Oct","modification":"2026-04-08T06:30:47.419Z","creation":"2019-03-26T23:59:07Z"},"accession":"S-EPMC6167406","cross_references":{"pubmed":["30220622"],"doi":["10.1016/S1470-2045(18)30500-X"]}}